New agreement aims to enhance pain management options in South Korea.
- Grünenthal has licensed Qutenza rights to BCWorld Pharm.
- The agreement focuses on enhancing pain management solutions.
- This partnership aims to improve patient access in South Korea.
Grünenthal announced it has granted exclusive rights to Qutenza, a topical patch for pain management, to BCWorld Pharm in South Korea. This agreement is expected to broaden the treatment options available for patients experiencing pain in the region. Qutenza, which contains capsaicin, is primarily used for neuropathic pain and other chronic pain conditions.
Under this licensing agreement, BCWorld Pharm will be responsible for the commercialization of Qutenza in South Korea. The collaboration aims to leverage BCWorld's expertise in the local pharmaceutical market to improve access to this important pain management option. As chronic pain continues to affect millions, this partnership may significantly impact patient care in South Korea.
This deal aligns with Grünenthal's commitment to expanding access to innovative pain relief solutions globally. Qutenza has already gained traction in various markets, and this licensing effort is a step towards more widespread usage in countries where it can benefit patients suffering from chronic pain.
